Set a new low for the stock price since May 2021. Competitors are challenging the valuation logic of Legend Biotech (LEGN.US)?

Entering May, Legend Biotech's stock price entered a new round of decline, plunging 10.55% on May 14, and the next day the stock price hit a low of $27.43, marking a new low since May 2021.

Zhitong FinanceMay 17 21:28

BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90

Futu NewsMay 17 00:31 · Ratings

Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says

MT NewswiresMay 16 23:07

Legend Biotech's Promising Outlook: Strong Demand, Capacity Expansion, and Market Leadership Drive Buy Rating

TipRanksMay 16 19:36 · Ratings

BOCOM INTL: The impact of drug price reform in the USA may be controllable but remains to be observed, continuing to promote innovation + valuation repair logic.

The recent executive order by the USA to lower drug prices is essentially a continuation of the most favored nation pricing policy from Trump's first term. However, there are still no specific implementation details, coupled with the interplay of various interest groups, leading to a certain degree of excessive concern in the current Sector.

Zhitong FinanceMay 16 15:35

China's top private equity disclosed "US stock report card": significantly increasing positions in Chinese concept stocks, optimistic about China's prospects.

The first quarter Hold Positions data of Chinese private investment institutions such as Hillhouse, Yiyuan, and Jinglin shows that they have all increased their investments in Chinese concept stocks; against the backdrop of this year's "East rising, West falling" market, it's clear that these private investment giants are optimistic about the prospects of China Assets.

cls.cnMay 16 14:31